171 related articles for article (PubMed ID: 16415021)
1. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.
Tchesnokov EP; Gilbert C; Boivin G; Götte M
J Virol; 2006 Feb; 80(3):1440-50. PubMed ID: 16415021
[TBL] [Abstract][Full Text] [Related]
2. Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.
Piret J; Goyette N; Eckenroth BE; Drouot E; Götte M; Boivin G
J Virol; 2015 Apr; 89(8):4636-44. PubMed ID: 25673718
[TBL] [Abstract][Full Text] [Related]
3. Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity.
Martin M; Azzi A; Lin SX; Boivin G
Antivir Ther; 2010; 15(4):579-86. PubMed ID: 20587851
[TBL] [Abstract][Full Text] [Related]
4. Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase.
Zarrouk K; Pham VD; Piret J; Shi R; Boivin G
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015044
[TBL] [Abstract][Full Text] [Related]
5. Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet.
Bonnafous P; Naesens L; Petrella S; Gautheret-Dejean A; Boutolleau D; Sougakoff W; Agut H
Antivir Ther; 2007; 12(6):877-88. PubMed ID: 17926642
[TBL] [Abstract][Full Text] [Related]
6. Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.
Tchesnokov EP; Obikhod A; Schinazi RF; Götte M
J Biol Chem; 2009 Sep; 284(39):26439-46. PubMed ID: 19622750
[TBL] [Abstract][Full Text] [Related]
7. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
Cihlar T; Fuller MD; Mulato AS; Cherrington JM
Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet.
Ducancelle A; Alain S; Petit F; Sanson Le Pors MJ; Mazeron MC
J Virol Methods; 2007 May; 141(2):212-5. PubMed ID: 17197042
[TBL] [Abstract][Full Text] [Related]
9. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
Ducancelle A; Champier G; Alain S; Petit F; Le Pors MJ; Mazeron MC
Antivir Ther; 2006; 11(4):537-40. PubMed ID: 16856628
[TBL] [Abstract][Full Text] [Related]
10. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
Cihlar T; Fuller MD; Cherrington JM
J Virol; 1998 Jul; 72(7):5927-36. PubMed ID: 9621055
[TBL] [Abstract][Full Text] [Related]
11. Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.
Chou S
Antiviral Res; 2017 Feb; 138():57-60. PubMed ID: 27940027
[TBL] [Abstract][Full Text] [Related]
12. [A novel colorimetric test to study the susceptibility of human cytomegalovirus DNA polymerase to foscarnet].
Ducancelle A; Alain S; Scieux C; Fillet AM; Petit F; Sanson-Le Pors MJ; Mazeron MC
Pathol Biol (Paris); 2005; 53(8-9):551-5. PubMed ID: 16084026
[TBL] [Abstract][Full Text] [Related]
13. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet.
Ducancelle A; Gravisse J; Alain S; Fillet AM; Petit F; Pors MJ; Mazeron MC
J Virol Methods; 2005 May; 125(2):145-51. PubMed ID: 15794984
[TBL] [Abstract][Full Text] [Related]
15. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.
Mousavi-Jazi M; Schloss L; Drew WL; Linde A; Miner RC; Harmenberg J; Wahren B; Brytting M
J Clin Virol; 2001 Dec; 23(1-2):1-15. PubMed ID: 11595579
[TBL] [Abstract][Full Text] [Related]
16. Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis.
Andouard D; Mazeron MC; Ligat G; Couvreux A; Pouteil-Noble C; Cahen R; Yasdanpanah Y; Deering M; Viget N; Alain S; Hantz S
Antiviral Res; 2016 May; 129():115-119. PubMed ID: 26872863
[TBL] [Abstract][Full Text] [Related]
17. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus.
Chou S; Lurain NS; Thompson KD; Miner RC; Drew WL
J Infect Dis; 2003 Jul; 188(1):32-9. PubMed ID: 12825168
[TBL] [Abstract][Full Text] [Related]
18. Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet.
Zarrouk K; Zhu X; Pham VD; Goyette N; Piret J; Shi R; Boivin G
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0039021. PubMed ID: 33875432
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.
Chou S
J Clin Virol; 2011 Apr; 50(4):287-91. PubMed ID: 21295516
[TBL] [Abstract][Full Text] [Related]
20. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.
Gilbert C; Boivin G
Antimicrob Agents Chemother; 2005 Dec; 49(12):4860-6. PubMed ID: 16304146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
